PubRank

M H Prins

Author PubWeight™ 199.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999 12.96
2 The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996 6.87
3 Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992 5.48
4 Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996 4.10
5 Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003 3.94
6 Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996 3.42
7 Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999 2.77
8 Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008 2.50
9 Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000 2.49
10 Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000 2.35
11 Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004 2.28
12 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013 2.24
13 Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev 2004 2.16
14 High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000 2.15
15 Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg 2011 2.14
16 Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost 2014 2.03
17 Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999 2.00
18 Deep-vein thrombosis. Lancet 1999 1.98
19 Triage of patients for short term observation after elective coronary angioplasty. Heart 2000 1.97
20 Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004 1.84
21 Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999 1.81
22 The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997 1.75
23 Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. ANTELOPE-Study Group. Thromb Haemost 2000 1.73
24 A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001 1.72
25 Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost 2010 1.69
26 Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Br J Surg 1996 1.68
27 Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost 2005 1.65
28 Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2004 1.63
29 Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost 1999 1.60
30 Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997 1.57
31 Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost 1997 1.56
32 Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997 1.54
33 Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000 1.49
34 Accuracy of single-detector spiral CT in the diagnosis of pulmonary embolism: a prospective multicenter cohort study of consecutive patients with abnormal perfusion scintigraphy. J Thromb Haemost 2005 1.46
35 Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost 2007 1.44
36 Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2005 1.43
37 Microcirculatory investigations to determine the effect of spinal cord stimulation for critical leg ischemia: the Dutch multicenter randomized controlled trial. J Vasc Surg 1999 1.43
38 A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000 1.43
39 Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995 1.41
40 EVAR suitability is not a predictor for early and midterm mortality after open ruptured AAA repair. Eur J Vasc Endovasc Surg 2011 1.41
41 Contribution of age and intimal lesion morphology to coronary artery wall mechanics in coronary artery disease. Clin Sci (Lond) 1995 1.41
42 Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S--a decision analysis. Thromb Haemost 2000 1.40
43 [Deep venous thrombosis: does recently improved knowledge lead to a real advance in the direction patient care?]. Ned Tijdschr Geneeskd 1996 1.39
44 Risk factors of arterial cardiovascular complications in patients with prior venous thromboembolism. Neth J Med 2011 1.38
45 Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000 1.32
46 Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2006 1.31
47 Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999 1.31
48 Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996 1.29
49 Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006 1.27
50 Management studies using a combination of D-dimer test result and clinical probability to rule out venous thromboembolism: a systematic review. J Thromb Haemost 2005 1.26
51 Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000 1.24
52 Lipoprotein(a) concentrations in women with a history of severe preeclampsia--a case control study. Thromb Haemost 1999 1.23
53 Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999 1.23
54 International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013 1.21
55 Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999 1.19
56 Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis. Ann Intern Med 1995 1.19
57 Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart 2008 1.17
58 Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004 1.16
59 Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med 1998 1.16
60 Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006 1.13
61 Major orthopaedic surgery and post-discharge DVT. Lancet 1996 1.09
62 Diagnosing acute pulmonary embolism: effect of chronic obstructive pulmonary disease on the performance of D-dimer testing, ventilation/perfusion scintigraphy, spiral computed tomographic angiography, and conventional angiography. ANTELOPE Study Group. Advances in New Technologies Evaluating the Localization of Pulmonary Embolism. Am J Respir Crit Care Med 2000 1.09
63 Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999 1.07
64 The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998 1.07
65 Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005 1.07
66 Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998 1.07
67 Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009 1.06
68 Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J Thromb Haemost 2009 1.02
69 Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005 1.02
70 Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000 1.01
71 Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost 2007 1.01
72 The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996 1.01
73 [Quality of life in children with sickle cell disease in Amsterdam area]. Ned Tijdschr Geneeskd 1999 1.00
74 The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999 1.00
75 Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis 1999 0.99
76 Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999 0.98
77 Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. Thromb Haemost 1999 0.97
78 Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005 0.97
79 Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res 2009 0.97
80 Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost 2011 0.96
81 Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group. Thromb Haemost 1998 0.96
82 Validation of the Dutch version of the Walking Impairment Questionnaire. Eur J Vasc Endovasc Surg 2008 0.95
83 Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands--The EXAMINE-AF study. A questionnaire survey. Int J Clin Pract 2007 0.95
84 Disability and functional assessment in former polio patients with and without postpolio syndrome. Arch Phys Med Rehabil 1999 0.95
85 Venous thromboembolism and occult malignancy. Thromb Res 2001 0.95
86 Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995 0.95
87 A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007 0.94
88 The 20210 G-->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999 0.92
89 Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997 0.92
90 Angioplasty or bypass for superficial femoral artery disease? A randomised controlled trial. Eur J Vasc Endovasc Surg 2004 0.92
91 Maternal smoking during pregnancy and childhood overweight and fat distribution: the KOALA Birth Cohort Study. Pediatr Obes 2013 0.91
92 Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 2011 0.89
93 Diagnostic strategies for the management of patients with clinically suspected deep-vein thrombosis. Curr Opin Pulm Med 1997 0.89
94 Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010 0.89
95 Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010 0.89
96 Feasibility of TEE-guided stroke risk assessment in atrial fibrillation-background, aims, design and baseline data of the TIARA pilot study. Neth Heart J 2011 0.88
97 Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 1999 0.88
98 The potential role of positron emission tomography in the detection of occult cancer in 25 patients with venous thromboembolism. Ann Oncol 2008 0.88
99 Potential of integrated [18F] fluorodeoxyglucose positron-emission tomography/CT in identifying vulnerable carotid plaques. AJNR Am J Neuroradiol 2011 0.87
100 Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2000 0.87
101 Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost 1999 0.87
102 Definition of the post-thrombotic syndrome, differences between existing classifications. Eur J Vasc Endovasc Surg 2005 0.87
103 Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2003 0.87
104 The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis 1998 0.87
105 Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med 2012 0.86
106 Peripheral arterial disease: public and patient awareness in The Netherlands. Eur J Vasc Endovasc Surg 2004 0.85
107 Adherence to a Mediterranean dietary pattern in early life is associated with lower arterial stiffness in adulthood: the Amsterdam Growth and Health Longitudinal Study. J Intern Med 2012 0.84
108 Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study. Neth Heart J 2010 0.84
109 Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002 0.84
110 Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life. Haemostasis 1998 0.83
111 Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haematol 1998 0.83
112 Treatment of venous thromboembolism. Thromb Haemost 1995 0.82
113 Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. Eye (Lond) 2006 0.82
114 Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study. Diabetologia 2012 0.82
115 Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice. Eur J Vasc Endovasc Surg 2010 0.82
116 Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999 0.82
117 Non-invasive diagnostic work-up of patients with clinically suspected pulmonary embolism; results of a management study. J Thromb Haemost 2004 0.82
118 The application of a Dutch consensus diagnostic strategy for pulmonary embolism in clinical practice. Neth J Med 2001 0.81
119 Blood coagulation and cancer: thrombosis and survival, clinical relevance and impact. An introduction. Pathophysiol Haemost Thromb 2009 0.81
120 Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor. Vasa 2004 0.81
121 Which factors are associated with the application of reperfusion therapy in ST-elevation acute coronary syndromes?. Lessons from the Euro Heart Survey on Acute Coronary Syndromes I. Cardiology 2006 0.81
122 Medical management of peripheral arterial disease. J Thromb Haemost 2005 0.81
123 Compression therapy for treating stage I and II (Widmer) post-thrombotic syndrome. Cochrane Database Syst Rev 2003 0.80
124 Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2003 0.79
125 Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2003 0.79
126 [From the Cochrane Library: increased walking distance through supervised exercise therapy in patients with intermittent claudication]. Ned Tijdschr Geneeskd 2008 0.79
127 Predictors of walking distance after supervised exercise therapy in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2009 0.78
128 Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. Eur J Intern Med 2010 0.78
129 The development and implementation of a regional network of physiotherapists for exercise therapy in patients with peripheral arterial disease, a preliminary report. BMC Health Serv Res 2005 0.78
130 Common alternative diagnoses in general practice when deep venous thrombosis is excluded. Neth J Med 2012 0.78
131 Transient thrombocytopenia after cardiac surgery in infants with Down syndrome. J Pediatr Hematol Oncol 1999 0.78
132 Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg 2000 0.78
133 Is contrast venography a valid surrogate outcome measure in venous thromboembolism prevention studies? J Thromb Haemost 2005 0.77
134 Should patients with venous thromboembolism and cancer be treated differently? Haemostasis 1999 0.77
135 Technegas versus (81m)Kr ventilation-perfusion scintigraphy: a comparative study in patients with suspected acute pulmonary embolism. J Nucl Med 2001 0.77
136 The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. J Thromb Haemost 2003 0.77
137 Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2000 0.77
138 Treatment for intermittent claudication and the effects on walking distance and quality of life. Vascular 2012 0.77
139 Early and mid-term results of a prospective observational study comparing emergency endovascular aneurysm repair with open surgery in both ruptured and unruptured acute abdominal aortic aneurysms. Vascular 2012 0.77
140 For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res 2000 0.77
141 A simple diagnostic strategy in hospitalized patients with clinically suspected pulmonary embolism. J Intern Med 2006 0.77
142 No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension: a prospective randomised open-label study with blinded endpoint assessment. Int J Cardiol 2009 0.76
143 From the Cochrane library: Ginkgo biloba for intermittent claudication. Vasa 2010 0.76
144 Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep vein thrombosis. J Thromb Haemost 2007 0.76
145 Recurrent deep vein thrombosis and two coagulation factor gene mutations: quo vadis? Thromb Haemost 1999 0.75
146 Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor. Haemostasis 2000 0.75
147 Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart 2002 0.75
148 The relationship between adherence and quality of treatment with vitamin K antagonists. J Thromb Haemost 2004 0.75
149 Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group. Heart 1998 0.75
150 Low-molecular-weight heparins: are they interchangeable? Haemostasis 2000 0.75
151 Does low-molecular-weight heparin reduce the costs of venous thromboembolism treatment? Haemostasis 2000 0.75
152 Fright of flight-related venous thromboembolism: evidence or emotion-based? Thromb Haemost 2001 0.75
153 Postintervention duration of anticoagulation in venous surgery. Phlebology 2013 0.75
154 Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis. Blood Coagul Fibrinolysis 2001 0.75
155 Availability of diagnostic facilities in the Netherlands for patients with suspected pulmonary embolism. ANTELOPE Study Group. Advances in New Technologies Evaluating the Localisation of Pulmonary Embolism. Neth J Med 2000 0.75
156 Venous thromboembolism and occult malignancy: an historical perspective. Haemostasis 2001 0.75
157 Nutritional status in patients with chronic pancreatitis. Eur J Clin Nutr 2013 0.75
158 Which is the outcome of the post-thrombotic syndrome? Thromb Haemost 1999 0.75
159 The effect of Fiberform, a low-phytate wheat fibre, on plasma lipids and blood pressure of women with familial hypercholesterolaemia. J Intern Med 1994 0.75
160 Which is the outcome of the post-thrombotic syndrome? Thromb Haemost 1999 0.75
161 Fibrin D-dimer measurement in suspected pulmonary embolism. Semin Vasc Med 2001 0.75
162 [Treatment of intermittent claudication; prospective randomized study in the BAESIC-Trial (bypass, angioplasty or endarterectomy patients with severe intermittent claudication)]. Ned Tijdschr Geneeskd 1996 0.75
163 Local endothelial function and leg symptoms in patients after deep vein thrombosis. J Thromb Haemost 2003 0.75
164 [No indication for thrombophilia screening in patients with idiopathic venous thromboembolism and their relatives]. Ned Tijdschr Geneeskd 2001 0.75
165 Acute pulmonary embolism: impact of selection bias in prospective diagnostic studies. ANTELOPE Study Group. Advances in New Technologies Evaluating the Localization of Pulmonary Embolism. Thromb Haemost 2001 0.75
166 A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis 2001 0.75
167 Who is at risk for occult cancer after venous thromboembolism? J Thromb Haemost 2006 0.75